Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination drug contains **paracetamol** (an analgesic and antipyretic that inhibits central prostaglandin synthesis to reduce pain and fever), **phenylephrine** (a sympathomimetic and alpha-adrenergic agonist acting as a nasal decongestant), **pheniramine** (an antihistamine that blocks H1 histamine receptors to relieve allergy symptoms such as sneezing, runny nose, and watery eyes), and **ascorbic acid** (vitamin C, an antioxidant included to compensate for increased needs during infection and to support immune function). The combination is formulated for the short-term treatment of symptoms associated with colds, influenza, and upper respiratory tract infections, such as headache, body aches, fever, nasal congestion, sneezing, and rhinorrhea[1][3][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + phenylephrine + pheniramine + ascorbic acid.